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harboring wild-type KRAS tumors were sorted into sub-
groups of 25 patients without abnormality in three mol-
ecules (BRAF, PIK3CA and Met) and 19 patients with 
abnormality in at least one of these three molecules. the 
former group showed significantly higher DCr and longer 
PFS following anti-egFr therapy than the latter group.
Conclusions Our data point to the usefulness of Met 
overexpression, in addition to BRAF and PIK3CA muta-
tions, as a new predictive marker for responsiveness to anti-
egFr Moabs in mCrC patients with wild-type KRAS. 
this study also suggests that application of multiple bio-
markers is more effective than the use of a single marker 
in selecting patients who might benefit from anti-egFr 
therapy.
Keywords Colorectal cancer · BRAF · PIK3CA · Pten · 
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Introduction
Cetuximab and panitumumab are monoclonal antibodies 
(Moabs) that inhibit the activation of the epidermal growth 
factor receptor (egFr) and its downstream pathways, 
namely the raS/raF/MaPK and the PI3K/Pten/akt 
axes [1, 2]. as the response rate (rr) to anti-egFr Moabs 
remains as low as 10–20 % in patients with metastatic 
colorectal cancer (mCrC) [2], several studies have been 
performed to identify markers predicting the efficacy of 
these agents. tumors carrying oncogenic KRAS mutations 
typically do not respond to anti-egFr Moabs therapy [3]. 
this finding led the european Medicines agency and, sub-
sequently, the US Food and Drug administration to limit 
the use of cetuximab and panitumumab only to patients 
with wild-type KRAS tumors [4]. However, since only 
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40–60 % of patients with wild-type KRAS tumors respond 
to anti-egFr Moab therapy, new predictive and prognos-
tic factors are actively being sought [5, 6]. In this regard, 
the presence of oncogenic deregulation of egFr and other 
members of its downstream signaling pathways, such as 
BRAF, PIK3CA, and Pten, has been shown to influence 
the responsiveness to cetuximab and panitumumab and 
could, therefore, help to identify nonresponder patients [4, 
6–10]. While many studies have demonstrated the BRAF 
mutation, PIK3CA mutation, and Pten overexpression as 
markers for resistance to anti-egFr Moab therapy, some 
failed to show such association [4, 7, 8, 10–13]. therefore, 
analysis of these genetic markers in different patient pop-
ulations, in particular in different ethnic groups, will help 
determine their clinical significance.
Furthermore, recent studies also have suggested that 
activation of Met, a tyrosine kinase that acts as a recep-
tor for hepatocyte growth factor (HgF) and can activate the 
raS/raF/MaPK and Pten/PI3K/akt pathways, may be 
a novel mechanism of cetuximab resistance in CrC [13–
18]. However, it remains unclear whether Met activation 
can serve as a predictive marker for the response to the 
anti-egFr therapy in patients with wild-type KRAS.
therefore, we investigated the status of Met expression 
together with Pten expression and mutations of BRAF and 
PIK3CA in tumors of Japanese mCrC patients with wild-
type KRAS. the main purpose of this study was to examine 
these genetic profiles for potential correlations with clinical 
response to anti-egFr Moab therapy.
Materials and methods
Patients
Clinical outcomes of anti-egFr Moab therapy were ret-
rospectively analyzed for possible associations with the 
molecular features of tumors in mCrC patients. the study 
enrolled 91 patients who were treated at the Department 
of gastroenterological Surgery and Medical Oncology, 
Kyorin University Hospital, between november 2008 and 
December 2012. all patients had presented with histologi-
cally confirmed mCrC and had been treated with salvage 
chemotherapy incorporating anti-egFr Moabs. Clini-
cal features of the patients and pathological profiles of the 
tumors were obtained from patient medical records.
all patients received cetuximab- or panitumumab-based 
therapy for mCrC (11 as first-line, 29 as second-line, 39 as 
third-line, and 12 as fourth-line or greater). Cetuximab, as 
monotherapy or in combination with irinotecan, was admin-
istered intravenously (i.v.) at a loading dose of 400 mg/m2 
over 2 h, followed by weekly doses administered at 250 mg/
m2 over 1 h. Panitumumab was administered i.v. every 
2 weeks at a dose of 6 mg/kg. treatment was continued 
until disease progression (PD) or toxicity occurred. Clini-
cal evaluation and tumor response was analyzed according 
to response evaluation Criteria in Solid tumors (reCISt) 
[19]. this study was approved by the research ethics Com-
mittee, Hospital of Kyorin University School of Medicine.
Mutational analysis of KRAS, BRAF, and PIK3CA 
by direct sequencing
Paraffin-embedded tissues (primary or metastatic) were 
sectioned at 10 μm thicknesses and mounted as three sepa-
rate slides per tissue. the resulting slides were treated three 
times with xylene and then washed with ethanol. to mini-
mize contamination by normal Dna, areas in which at least 
70 % of the cells exhibited disease-specific pathology were 
dissected under a binocular microscope, from which Dna 
was extracted using the QIaamp FFPe tissue Kit (QIa-
gen). Segments of the KRAS, BRAF, and PIK3CA genes 
were amplified using gene-specific primers and subjected 
to direct Dna sequencing as previously described [4, 
13, 20]. KRAS point mutations were screened for codons 
12 and 13 within exon 2, two hot spots that cumulatively 
include >95 % of mutations in this gene [21]. BRAF muta-
tions were screened for V600e within exon 15, in which 
>95 % of point mutations occur [7, 9]. PIK3CA mutations 
were screened within exons 9 and 20, in which >80 % of 
point mutations occur [4, 10, 12].
Immunohistochemistry of Pten and Met
Pten and Met expression levels were evaluated by 
immunohistochemistry performed on 4-μm tissue sec-
tions of paraffin-embedded specimens. Pten was assessed 
using the 17.a mouse Moab (1:25 dilution; neomarkers, 
thermo Fisher Scientific Inc., Fremont, Ca); Met was 
assessed using the SP44 rabbit Moab (Spring Biosciences, 
Pleasanton, Ca) [22, 23]. negative controls were incubated 
with nonimmune solution instead of primary antibody. 
endothelial cells and hepatocellular carcinoma cells were 
used as positive controls for Pten and Met expression, 
respectively. the Pten and Met staining intensities were 
evaluated by a pathologist (Y.O.) who was blinded to the 
diagnosis of individual patients.
to our knowledge, there currently are no validated scor-
ing systems for interpretation of Pten or Met staining 
intensity. Both Pten and Met are localized primarily in 
the cytoplasm [11, 24, 25]; we therefore adopted a scor-
ing system that has been used for other cytoplasmic pro-
teins and is based on the intensity of immunoreactivity and 
percentage of stained cells [26, 27]. Specifically, intensity 
was scored according to a four-tier system: 0, no staining; 
1, weak; 2, moderate; and 3, strong. an additional one, two, 
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or three points were assigned if the percentage of positive 
cells was <25, 25–50 %, or >50 %, respectively [4, 11].
We defined normal Pten expression as a score of 4 or 
greater; scores of 0–3 were classified as loss of expression 
(Fig. 1a, b). We defined normal/low expression of Met 
as a score of 0–3; scores of 4 or greater were classified as 
Met overexpression (Fig. 1c, d).
Statistical analysis
Comparison of categorical variables was performed with 
the χ2 test or the Fisher’s exact test. the progression-free 
survival (PFS) and overall survival (OS) were calculated 
using the Kaplan–Meier method. Comparisons between dif-
ferent groups were performed using log-rank tests. to iden-
tify independent biomarkers, multivariate analyses were 
performed using a logistic regression model for response 
and a Cox regression model for PFS and OS. two-tailed 
P values of <0.05 were considered significant. all analyses 
were performed using SPSS software (SPSS for Windows 
Version 15.0; SPSS Inc., Chicago, Il).
Results
Patient characteristics
all study patients were Japanese; they were 66 men and 25 
women with a mean age of 67 years (range 38–85 years). 
at a median follow-up of 13.3 months (range 1.3–
24.4 months), 78 patients (86 %) had progressed, and 41 
patients (45 %) had died. response to anti-egFr therapy 
was evaluable in all patients. We observed no patients with 
complete response (Cr), 27 with partial response (Pr), 24 
with stable disease (SD), and 40 with PD. therefore, the 
overall rr was 29.7 %, and the disease control rate (DCr) 
was 56.0 %. In the whole group, PFS and OS were 3.9 and 
13.3 months, respectively.
KRAS mutational analysis
the mutational status of KRAS exon 2 was determined 
in all patients, with mutations detected in 24 patients 
(26.4 %). Pr was observed in 26 patients with wild-type 
KRAS (38.8 %) and in one patient with mutation (4.2 %). 
rr and DCr were significantly lower in patients with 
KRAS mutations than in those with wild-type KRAS: For 
rr, the values were 4.2 versus 38.8 % (P < 0.001); for 
DCr, the values were 16.7 versus 70.2 % (P < 0.001). 
Median PFS was significantly shorter in patients whose 
tumors carried KRAS mutations than in those without such 
mutations (2.0 vs. 5.4 months; hazard ratio (Hr) 1.67; 
95 % confidence interval (CI) 1.29–2.14; P < 0.001; Sup-
plementary table 1, Supplementary Fig. 1a). Median 
OS was shorter in patients whose tumors carried KRAS 
mutations than in those without such mutations, although 
the difference was not statistically significant (9.9 vs. 
13.4 months; Hr 1.35; 95 % CI 0.96–1.85; P = 0.069; 
Fig. 1  representative examples 
of immunohistochemical stain-
ing in colorectal cancer. Pten, 
normal expression (a) and loss 
of expression (b); Met, low 
expression (c) and  
overexpression (d)
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Supplementary table 1, Supplementary Fig. 1B). thus, 
our results indicated that KRAS mutations were repro-
ducibly associated with less favorable outcomes for anti-
egFr Moab therapy, consistent with the previous reports. 
therefore, our further analyses focused primarily on 
patients with wild-type KRAS tumors. table 1 summarizes 
the characteristics of the 67 patients who harbored tumors 
with wild-type KRAS genes.
BRAF mutational analysis
the mutational status of BRAF exon 15 was determined in 
all but one patient. Five (7.7 %) of 65 patients with wild-
type KRAS harbored BRAF mutations, while none of 24 
patients with KRAS mutation harbored mutations in BRAF 
(Supplementary table 2). none of the BRAF mutant patients 
exhibited a response to Moab therapy. In the patients with 
wild-type KRAS, the presence of the BRAF mutation was 
associated with a significantly reduced DCr (P = 0.002; 
table 2). In this cohort, BRAF mutations were signifi-
cantly associated with shorter PFS (1.2 vs. 5.5 months; 
Hr 3.03; 95 % CI 1.78–4.86; P < 0.001; table 3, Fig. 2a) 
and shorter OS (3.1 vs. 16.8 months; Hr 3.74; 95 % CI 
2.11–6.53; P < 0.001; table 3, Fig. 2b). the PFS and OS 
of these patients were shorter than those of patients with 
KRAS mutations (median PFS 1.2 vs. 2.0 months; Hr 1.70; 
95 % CI 0.95–2.83; P = 0.037; and median OS 3.1 vs. 
9.9 months; Hr 0.52; 95 % CI 0.31–0.92; P = 0.009).  
PIK3CA mutational analysis
the mutational status of PIK3CA was determined in 84 
patients. Mutations were detected in three (13 %) of 23 
patients with KRAS mutations and three (5.2 %) of 58 
patients with wild-type KRAS (P = 0.339; Supplementary 
table 2). none of the PIK3CA-mutant patients exhibited 
a response to Moab therapy. When analysis was limited 
to patients with wild-type KRAS, DCr was significantly 
associated with the PIK3CA mutational status (P = 0.027; 
table 2). PIK3CA mutations also were significantly asso-
ciated with shorter PFS (1.8 vs. 5.4 months; Hr 2.22; 
95 % CI 1.07–3.86; P = 0.005) and shorter OS (5.1 vs. 
15.4 months; Hr 2.16; 95 % CI 0.84–4.29; P = 0.031) 
(table 3, Fig. 2c, d).
Pten immunohistochemical evaluation
Of 91 patients, 75 patients were evaluable for Pten. 
twenty-four patients (32 %) showed loss of Pten expres-
sion in the cytoplasmic compartment of the tumor cells. no 
significant correlation was found between Pten expres-
sion and KRAS mutational status (Supplementary table 2). 
no significant association between Pten expression and 
rr, DCr, PFS, or OS was detected in patients with wild-
type KRAS, although patients with loss of Pten tended to 
show lower rr and DCr than those with normal Pten 
expression (tables 2, 3, Fig. 2e, f).
Met immunohistochemical evaluation
Of 91 patients, 75 patients were evaluable for Met, with 
overexpression of the protein detected in 36 samples (48 %) 
Table 1  Characteristics of patients with wild-type KRAS (n = 67)
FOLFIRI folinic acid, fluorouracil, and irinotecan, FOLFOX folinic 
acid, fluorouracil, and oxaliplatin
Characteristics n %
age
 <70 41 61.2
 >70 26 29.8
gender
 Male 50 74.6
 Female 17 25.4
evaluated tumor
 Primary 63 94.3
 Metastasis 4 5.7
Stage at diagnosis
 II and III 21 31.3
 IV 46 68.7
Primary tumor location
 Cecum 1 1.5
 ascending colon 7 11.1
 transverse colon 3 4.5
 Descending colon 2 3.0
 Sigmoid colon 23 34.3
 rectum 32 47.8
tumor differentiation
 Well/moderate 60 96.7
 Poor 2 3.3
Site of metastasis
 liver 49 73.1
 lung 33 49.3
 Peritoneum 13 19.4
 Others 13 19.4
egFr-targeted therapies
 Cetuximab 25 37.3
 Cetuximab + irinotecan 19 28.4
 Cetuximab + FOlFIrI/FOlFOX 7 10.4
 Panitumumab 13 19.4
 Panitumumab + irinotecan 3 4.5
anti-egFr antibody administration line
 1st 10 14.9
 2nd 23 34.3
 3rd 28 41.8
 4th or greater 6 9.0
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(Supplementary table 1). as with Pten, there was no cor-
relation between Met expression and KRAS mutational 
status (Supplementary table 2). In 54 wild-type KRAS 
patients evaluable for Met, Met overexpression was asso-
ciated with lower DCr (53.9 % vs. 82.1 %, P = 0.040; 
table 2). Furthermore, Met overexpression was associ-
ated with shorter PFS (4.7 vs. 6.8 months; Hr 1.46; 95 % 
CI 1.06–2.02; P = 0.018; table 3), but exhibited no cor-
relation with OS (12.8 vs. 15.4 months; Hr 1.16; 95 % CI 
0.73–1.82; P = 0.524) in this patient subgroup (table 3, 
Fig. 2g, h).
Multivariate analyses
Multivariate analysis among patients with wild-type KRAS 
did not identify BRAF mutation, PIK3CA mutation, loss of 
Pten expression, or Met overexpression as independent 
biomarkers for lower rr and DCr. However, the BRAF 
mutation and Met overexpression were identified as inde-
pendent factors for shorter PFS among patients with wild-
type KRAS (BRAF, P = 0.004; Met, P = 0.046) (table 4). 
the BRAF mutation was also identified as an independent 
factor for shorter OS among patients with wild-type KRAS 
(OS, P = 0.001) (table 5).
Discussion
In the present study, the Met expression, Pten expres-
sion, and mutations of BRAF and PIK3CA in mCrC 
patients with wild-type KRAS were investigated in associa-
tion with clinical response to anti-egFr Moab therapy. 
the most striking finding in this study was that Met over-
expression was associated with lower DCr and shorter 
Table 2  effect of biomarkers 
on rr and DCr of patients 
with wild-type KRAS: univariate 
analysis
PR partial response, SD stable 
disease, PD disease progression, 
RR response rate, DCR disease 
control rate
n Pr SD PD rr (%) P DCr (%) P
BRAF
 Wild 60 24 21 15 40 75.0
 Mutant 5 0 0 5 0 0.149 0 0.002
PIK3CA
 Wild 58 22 20 16 37.9 72.4
 Mutant 3 0 0 3 0 0.547 0 0.027
Pten
 normal expression 39 15 14 10 46.2 74.4
 loss of expression 15 3 5 7 20.0 0.120 46.7 0.192
Met
 normal/low expression 28 12 11 5 42.9 82.1
 Overexpression 26 9 5 12 34.6 0.586 53.9 0.040
Table 3  effect of biomarkers on PFS and OS in patients with wild-type KRAS: univariate analysis
PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval
n % PFS OS
Median 
(months)
Hr (95 %CI) P Median 
(months)
Hr (95 %CI)   P
BRAF
 Wild-type 60 92.3 5.5  3.03 16.8  3.74
 Mutant 5 7.7 1.2 (1.78–4.86) <0.001 3.1 (2.11–6.53) <0.0001
PIK3CA
 Wild-type 58 95.1 5.4  2.22 15.4  2.16
 Mutant 3 4.9 1.8 (1.07–3.86) 0.005 5.1 (0.84–4.29) 0.031
Pten
 normal expression 39 72.2 6.2  1.14 13.4  1.12
 loss of expression 15 27.8 3.7 (0.81–1.57) 0.429 15.4 (0.07–1.74) 0.617
Met
 normal/low expression 28 51.9 6.8  1.46 15.4  1.16
 Over expression 26 48.1 4.7 (1.06–2.02) 0.018 12.8 (0.73–1.82) 0.524
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Fig. 2  a Progression-free survival (PFS) and b overall survival (OS) 
in wild-type KRAS patients classified by BRAF mutational status. c 
Progression-free survival (PFS) and d overall survival (OS) in wild-
type KRAS patients classified by PIK3CA mutational status. e Pro-
gression-free survival (PFS) and f overall survival (OS) in wild-type 
KRAS patients classified by Pten expression status. g Progression-
free survival (PFS) and h overall survival (OS) in wild-type KRAS 
patients classified by Met expression status
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PFS in patients with wild-type KRAS. One previous study 
reported an association of Met overexpression with the 
response to anti-egFr therapy in mCrC [13], although 
those researchers did not report the KRAS status of their 
study subjects. to the best of our knowledge, the present 
study is the first to clarify an association of Met over-
expression with inferior clinical response to anti-egFr 
Moabs in mCrC patients with wild-type KRAS. the rate 
of Met overexpression in mCrC in the present study was 
48 %, similar to those examined in the previous studies 
(17–79 %) [13, 28, 29].
Met is involved in many mechanisms of cancer 
proliferation and metastasis. Met contains a tyrosine 
kinase domain that initiates a range of signals to regu-
late various cellular functions [30]. Met can activate the 
raS/raF/MaPK and Pten/PI3K/akt pathways by itself 
or via egFr transphosphorylation [15–18]. In fact, Met 
overexpression or genetic alteration has been shown to play 
a role in the pathogenesis of several tumor types. In CrC, 
overexpression of Met has been suggested to be associ-
ated with tumor progression [28, 31]. In addition, Met 
also contributes to cancer resistance against egFr inhibi-
tors through bypass signaling. In nonsmall cell lung can-
cer, amplification of Met is associated with resistance to 
gefitinib, the reversible egFr tyrosine kinase inhibitor, 
via erbB3 activation [17, 18, 32]. resistance in that exam-
ple is mediated by Met-erbB3 transactivation, leading to 
restored signaling via the PI3K/aKt pathway [14]. Our 
present data revealed that Met overexpression is associ-
ated with shorter PFS, but not with altered OS, in mCrC 
patients with wild-type KRAS who received anti-egFr 
Moabs, suggesting that Met contributes to resistance 
against these therapies. If confirmed, these results attest to 
the feasibility of the recent development of Met-targeted 
agents against malignant diseases, a therapeutic approach 
that has already been reported in several phase I and II 
trials [33]. Met-targeted agents, alone or in combination 
with egFr inhibitors, may offer the potential for improv-
ing patients’ outcome in mCrC.
this study also adds to the growing evidence that BRAF 
mutational status predicts efficacy of anti-egFr therapy in 
mCrC patients with wild-type KRAS. therefore, assess-
ment of BRAF mutations before initiation of anti-egFr 
therapy appears to be justified in this patient group. How-
ever, the clinical impact of BRAF gene testing depends on 
the prevalence of BRAF mutations. In this study, the fre-
quency of BRAF mutations was 5 %, a value lower than 
that previously reported (7.9–16.6 %), possibly reflecting 
the fact that BRAF mutation is a negative prognostic marker 
that affects OS [34, 35]. In the present study, OS was 
shorter in BRAF-mutated patients compared with patients 
with wild-type BRAF, an observation that is consistent with 
the results of previous studies [4, 34, 35]. therefore, some 
patients with BRAF mutations may not have survived long 
enough to be recruited into this study. the frequency of 
BRAF mutations might have been higher in a prospective 
study, which is expected to enroll all CrC patients. In addi-
tion, the prevalence of BRAF mutations was reported to be 
lower in asian people than in Western people [34]. taken 
together, these data suggest that the clinical relevance of 
analyzing BRAF mutation in asian mCrC patients should 
be assessed by prospective studies in the future.
the frequency of PIK3CA mutations in the present 
study (8 %) was comparable to those in previous reports 
(7–18 %) [4, 10, 25]. Previous studies employing wild-type 
KRAS patients generally reported shorter median PFS or 
OS in PIK3CA-mutant patients than in patients with wild-
type PIK3CA [4, 7, 10]. In concordance with these results, 
our patients with PIK3CA mutation showed significantly 
shorter PFS and OS and lower DCr than those without 
mutation. the present results confirmed that mutation of 
PIK3CA is also a predictive marker for response to anti-
egFr Moab.
low Pten expression has been associated with shorter 
PFS in CrCs treated by anti-egFr Moabs in several 
reports [4, 11, 25], while no correlation was demonstrated 
in another report [8, 13]. We did not detect any association 
between Pten expression status and clinical response to 
anti-egFr Moab therapy. this discrepancy may reflect 
differences in patient characteristics or study design, and 
notably, the distinct IHC scoring algorithms used in the 
present study. the use of a standardized methodology for 
assessment of Pten expression would be crucial in the 
future studies.
this study has some limitations. Our study was per-
formed retrospectively in a relatively small and heterogene-
ous population. the majority of our population (90 %) was 
treated with two or more chemotherapy regimens before 
anti-egFr Moab therapy. In addition, the anti-egFr 
Table 4  effect of biomarkers on PFS in patients with wild-type 
KRAS: multivariate analysis
CI confidence interval
Variables Hazard ratio P 95 % CI
BRAF  (wild-type/mutant) 8.455 0.004 2.009–35.588
Met (normal/overexpression) 2.029 0.046 1.014–4.061
Table 5  effect of biomarkers on OS in patients with wild-type 
KRAS: multivariate analysis
CI confidence interval
Variables Hazard ratio P 95 % CI
BRAF (wild-type/mutant) 9.648 0.001 2.473–37.648
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treatment protocols were heterogeneous. the discrepancy 
observed in the results between univariate and multivari-
ate analyses might reflect these factors. Our findings there-
fore should be validated in subsequent prospective studies 
before they are applied in the clinical practice.
In conclusion, our data point out the usefulness of Met 
overexpression and mutations of BRAF, as a new predic-
tive marker for response to anti-egFr Moabs in mCrC 
patients with wild-type KRAS. Using these two genes may 
be more useful for predicting the response to anti-egFr 
Moabs. these results support the emerging view that a 
comprehensive assessment of genetic alterations in egFr 
signaling pathways will enable an accurate identification 
of patients who will benefit from anti-egFr treatment 
and other molecular-targeting therapies, including Met 
inhibitors.
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